Description: Vigil Neuroscience, Inc., a biotechnology company, discovers and develops novel therapeutics that take advantage of breakthroughs in science and human genetics of microglia. It harnesses the power of microglia for the treatment of neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.
Home Page: www.vigilneuro.com
VIGL Technical Analysis
1 Broadway
Cambridge,
MA
02142
United States
Phone:
857 254 4445
Officers
| Name | Title |
|---|---|
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | Pres, CEO & Director |
| Ms. Jennifer Ziolkowski CPA, CPA | Chief Financial Officer |
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Chief Medical Officer |
| Park Guo CPA | Accounting Mang. |
| Kelly Neelon Ph.D. | VP of CMC & Technical Operations |
| Ms. Sarah Carmody | VP of Investor Relations & Corp. Communications |
| Mr. Christopher Verni J.D. | Gen. Counsel |
| April Effort M.B.A., M.S. | Head of Corp. Devel. |
| Mr. Evan A. Thackaberry DABT, Ph.D. | Sr. VP & Head of Early Devel. |
| Mr. Charles Maggs | Head of FP&A |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1202 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-01-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 52 |